Previous 10 | Next 10 |
3 High Volume Penny Stocks For Your January Watchlist While trading penny stocks and blue chips has gotten off to a rough start this week, many investors are optimistic about the future. With the Dow Jones Industrial Average down by more than 500 points and the S&P 500 down by aroun...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! I hope you enjoyed the long weekend, but it’s time to get back into investing with the biggest pre-market stock movers for Tuesday! Source: f11photo/Shutterstock.com New agreements, FDA ...
Brickell Biotech, Inc. (BBI) Q3 2021 Results Conference Call November 09, 2021 04:30 PM ET Company Participants Garth Russell - IR, LifeSci Advisors Rob Brown - CEO Bert Marchio - CFO Monica Luchi - Chief Medical Officer Deepak Chadha - Chief R&D Officer Andy Sklawer - COO Conference Call...
Brickell Biotech (NASDAQ:BBI): Q3 GAAP EPS of -$0.16 misses by $0.03. Revenue of $0.13M (-7.1% Y/Y) misses by $0.02M. Press Release For further details see: Brickell Biotech EPS misses by $0.03, misses on revenue
Announced positive topline results from the Phase 3 pivotal clinical studies of sofpironium bromide gel, 15% in primary axillary hyperhidrosis patients; plan to submit a New Drug Application (NDA) to the FDA in mid-2022 Development of DYRK1A inhibitors is ongoing, including a pl...
BOULDER, Colo., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatolo...
Brickell Biotech (NASDAQ:BBI) dropped 29% premarket after it priced its earlier announced underwritten public offering of 26.32M shares at $0.38/share. Underwriters granted 30-day option to purchase up to 3.95M shares. Offer is expected to close on Nov.1. Gross proceeds are exp...
BOULDER, Colo., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell”), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatolo...
BOULDER, Colo., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell”), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatolo...
3 Penny Stocks That Could Explode in November 2021 If you’re looking for penny stocks that could explode, there are hundreds of options to choose from. And while part of finding penny stocks to buy is looking at fundamentals, the main cause of movement tends to be speculation...
News, Short Squeeze, Breakout and More Instantly...
Brickell Biotech Inc. Company Name:
BBI Stock Symbol:
NYSE Market:
New name, logo, website, and branding reflect the Company’s strategic shift toward developing potentially groundbreaking autoimmune and inflammatory disease therapies Company to begin trading under new ticker symbol “FRTX” on September 8, 2022 Compan...
Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 Development of BBI-10 and next-generation kinase inhibitors advancing through early precl...
BOULDER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoi...